文献速递神经肿瘤神经重症

雌二醇重编程小胶质细胞塑造免疫抑制微环境促进乳腺癌脑转移

Estradiol Reprograms Microglia to Create an Immune‑Suppressed Niche Permissive to Breast Cancer Brain Metastasis.
PubMed 文献 · Neuro Oncol · 2026-07-29

本研究利用自发与实验性乳腺癌脑转移模型,通过单细胞RNA测序和多参数流式细胞术,明确雌二醇(E2)在脑转移各阶段抑制小胶质细胞免疫监视与免疫激活程序、减少效应免疫细胞募集;抑制雌激素可重新激活小胶质细胞抗肿瘤信号,并与全脑放疗协同显著减缓脑转移进展。

要点

  • E2抑制小胶质细胞免疫监视与免疫激活,减少效应免疫细胞向脑转移灶募集。
  • 抑制雌激素可恢复小胶质细胞抗肿瘤反应并增加效应免疫细胞入脑。
  • E2抑制与放疗协同显著减缓晚期脑转移进展。

核心结论

  • E2通过小胶质细胞免疫抑制加速乳腺癌脑转移进展,支持将内分泌治疗作为ER阴性乳腺癌脑转移的辅助治疗进行评估。

研究设计与样本

  • 采用自发与实验性乳腺癌脑转移模型,结合单细胞RNA测序和多参数流式细胞术分析E2及E2抑制对脑免疫细胞群体的影响。
  • 使用小胶质细胞清除和T细胞共培养研究小胶质细胞在E2诱导脑转移中的作用。
  • 在模拟晚期脑转移的临床前模型中测试单独E2抑制及联合全脑放疗的效果。

主要发现

  • E2从脑转移早期到晚期抑制小胶质细胞的免疫监视和免疫激活程序,抑制效应免疫细胞向脑转移灶募集。
  • 抑制雌激素可重新激活小胶质细胞抗肿瘤信号并增加效应免疫细胞向脑内募集。
  • E2处理荷瘤小鼠的小胶质细胞促进T细胞扩增、效应潜能及CD8⁺T细胞杀伤肿瘤细胞的能力降低。
  • 抑制雌激素重新激活有效抗肿瘤反应,并与放疗协同显著减缓脑转移进展。

临床怎么用

  • 提示对绝经前年轻乳腺癌患者,内分泌干预可能改善脑转移免疫微环境并增强放疗效果。
  • 支持在ER阴性乳腺癌脑转移中评估内分泌治疗作为辅助治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Young age is an independent risk factor for the development of breast cancer brain metastases (BM). Prior work showed that 17β-estradiol (E2), the predominant premenopausal hormone, promotes BM of tumors intrinsically unresponsive to E2, in part through modulating estrogen receptor-alpha expressing (ERα⁺) glial cells. However, how E2 reshapes the brain tumor microenvironment (TME), particularly microglia‑mediated immunity, and its impact to BM progression remains unclear. METHODS: scRNA sequencing and multiparametric flow cytometry were used to define the impact of E2 and E2-suppression on brain immune-cell populations across different stages of BM progression using spontaneous and experimental models of BM. Depletion of microglia and T-cell co-cultures were used to study microglia's role in E2-induced BM. The effects of E2-suppression alone or in combination with whole brain radiotherapy were tested in preclinical models mimicking late-stage BM. RESULTS: E2 repressed immune surveillance and immune activation programs in microglia from early to late stages of brain metastatic progression, suppressing recruitment of effector immune cells to BM. Estrogen suppression, in turn reactivated anti-tumoral signaling in microglia and increased recruitment of effector immune cells to the brain. Microglia from E2-treated BM-bearing mice showed a reduced capacity to promote T-cell expansion, effector potential, and CD8⁺T cell-mediated tumor cell killing. Conversely, E2-suppression reactivated an effective anti-tumoral response and synergized with RT to significantly decrease BM progression. CONCLUSION: These findings reveal a previously unrecognized mechanism by which E2 accelerates BC‑BM progression through microglial immunosuppression and support evaluation of endocrine therapies as adjunct treatments for ER⁻ breast cancer brain metastases. Brain metastases from breast cancer are especially common in younger women, but the reasons why are unclear. This study investigated how the hormone estrogen (E2) influences the brain’s immune environment during metastasis. We found that E2 suppresses microglia-the brain’s immune sentinels-and limits the activity and recruitment of cancer‑fighting T cells. Removing or blocking E2 restored microglial defenses, increased immune cell entry into the brain, and improved the effectiveness of radiation therapy. These findings show that estrogen helps create a brain environment that supports tumor growth and suggest that blocking estrogen may improve treatment even for estrogen-receptor-negative breast cancers.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Alvarez-Eraso KLF, Contreras-Zárate MJ, Goodspeed A, et al. Estradiol Reprograms Microglia to Create an Immune‑Suppressed Niche Permissive to Breast Cancer Brain Metastasis. Neuro Oncol. 2026. PMID: 42528266. doi:10.1093/neuonc/noag173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。